2nd Pediatric Discipline, Department of Mother and Child, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
2nd Pediatric Clinic, Emergency Clinical Hospital for Children, 400177 Cluj-Napoca, Romania.
Int J Mol Sci. 2021 Dec 17;22(24):13578. doi: 10.3390/ijms222413578.
Pediatric autoimmune liver disorders include autoimmune hepatitis (AIH), autoimmune sclerosing cholangitis (ASC), and de novo AIH after liver transplantation. AIH is an idiopathic disease characterized by immune-mediated hepatocyte injury associated with the destruction of liver cells, causing inflammation, liver failure, and fibrosis, typically associated with autoantibodies. The etiology of AIH is not entirely unraveled, but evidence supports an intricate interaction among genetic variants, environmental factors, and epigenetic modifications. The pathogenesis of AIH comprises the interaction between specific genetic traits and molecular mimicry for disease development, impaired immunoregulatory mechanisms, including CD4+ T cell population and Treg cells, alongside other contributory roles played by CD8+ cytotoxicity and autoantibody production by B cells. These findings delineate an intricate pathway that includes gene to gene and gene to environment interactions with various drugs, viral infections, and the complex microbiome. Epigenetics emphasizes gene expression through hereditary and reversible modifications of the chromatin architecture without interfering with the DNA sequence. These alterations comprise DNA methylation, histone transformations, and non-coding small (miRNA) and long (lncRNA) RNA transcriptions. The current first-line therapy comprises prednisolone plus azathioprine to induce clinical and biochemical remission. Further understanding of the cellular and molecular mechanisms encountered in AIH may depict their impact on clinical aspects, detect biomarkers, and guide toward novel, effective, and better-targeted therapies with fewer side effects.
儿科自身免疫性肝病包括自身免疫性肝炎(AIH)、自身免疫性硬化性胆管炎(ASC)和肝移植后新发 AIH。AIH 是一种特发性疾病,其特征是免疫介导的肝细胞损伤与肝细胞破坏相关,导致炎症、肝功能衰竭和纤维化,通常与自身抗体相关。AIH 的病因尚未完全阐明,但有证据表明遗传变异、环境因素和表观遗传修饰之间存在复杂的相互作用。AIH 的发病机制包括特定遗传特征与疾病发展的分子模拟之间的相互作用、免疫调节机制受损,包括 CD4+T 细胞群和调节性 T 细胞,以及 CD8+细胞毒性和 B 细胞产生自身抗体的其他作用。这些发现描绘了一个复杂的途径,包括基因与基因、基因与环境的相互作用,以及各种药物、病毒感染和复杂的微生物群。表观遗传学通过遗传和可逆的染色质结构修饰来强调基因表达,而不干扰 DNA 序列。这些改变包括 DNA 甲基化、组蛋白转化以及非编码小(miRNA)和长(lncRNA)RNA 转录。目前的一线治疗包括泼尼松龙加硫唑嘌呤诱导临床和生化缓解。进一步了解 AIH 中遇到的细胞和分子机制可能会描述它们对临床方面的影响,检测生物标志物,并指导开发新的、有效的、更有针对性的治疗方法,减少副作用。